Equities

CASI Pharmaceuticals Inc

CASI:NAQ

CASI Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)6.73
  • Today's Change-0.03 / -0.44%
  • Shares traded5.59k
  • 1 Year change+226.71%
  • Beta0.6483
Data delayed at least 15 minutes, as of Sep 19 2024 16:03 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments195049
Total Receivables, Net10139.80
Total Inventory166.141.91
Prepaid expenses2.562.981.69
Other current assets, total121.46--
Total current assets597362
Property, plant & equipment, net121322
Goodwill, net------
Intangibles, net1.841.0612
Long term investments1.694.4040
Note receivable - long term------
Other long term assets0.774.122.18
Total assets7596138
LIABILITIES
Accounts payable4.443.294.79
Accrued expenses12128.40
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total01.90--
Total current liabilities171713
Total long term debt1900
Total debt1900
Deferred income tax------
Minority interest02223
Other liabilities, total151217
Total liabilities515254
SHAREHOLDERS EQUITY
Common stock0.000.001.40
Additional paid-in capital696692695
Retained earnings (accumulated deficit)(661)(637)(606)
Treasury stock - common(9.6)(9.33)(8.03)
Unrealized gain (loss)------
Other equity, total(1.2)(0.7)1.95
Total equity244585
Total liabilities & shareholders' equity7596138
Total common shares outstanding131314
Treasury shares - common primary issue0.410.280.01
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.